Pituitary Tumor Clinical Trial
Official title:
Comparative Low and High Dose of Dexmedethomidine Can Stabilize Hemodynamics and Blood Loss in Pituitary Tumor Removal by Transphenoid Approach
Transnasal transsphenoidal (TNTS) resection of pituitary tumors involves wide fluctuation in hemodynamic parameter and causes hypertension and tachycardia due to intense noxious stimuli during various stages of surgery. None of routinely used anesthetic agents effectively blunts the undesirable hemodynamic responses, and therefore usually there is a need to use increased doses of anesthetic agents. Dexmedetomidine (DEX) an α-2 adrenergic receptor agonist, because its sympatholytic and antinociceptive properties may ensure optimal intraoperative hemodynamic stability during critical moments of surgical manipulation. In addition, DEX reduced the anesthetic requirement with rapid recovery at the end of surgery. The main aim of the study was to evaluate the effect of DEX on perioperative hemodynamics, anesthetic requirements
DEX as an anesthetic adjuvant improved hemodynamic stability and decreased anesthetic requirements in patients undergoing TNTS resection of pituitary tumor. In addition, DEX provided better surgical field exposure conditions and early recovery from anesthesia ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04529356 -
The TMS Treatment for Postoperative Headache in GH Tumor
|
N/A | |
| Completed |
NCT03363126 -
Visual Outcome After Transsphenoidal Surgery for Pituitary Macroadenoma
|
N/A | |
| Completed |
NCT04212793 -
Detection of PitNET Tissue During TSS Using Bevacizumab-800CW
|
Phase 1 | |
| Recruiting |
NCT03309319 -
A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas
|
N/A | |
| Terminated |
NCT04106531 -
Validation of a Quality of Life Metric "Prolac-10"
|
||
| Recruiting |
NCT03719781 -
Postoperative Cognitive Dysfunction in Patients Undergoing Pituitary Removal Surgery
|
||
| Recruiting |
NCT01556230 -
Prospective Study of Clinically Nonfunctioning Pituitary Adenomas
|
||
| Recruiting |
NCT01368133 -
The Observational Study of Growth Hormone-secreting Pituitary Tumors
|
N/A | |
| Withdrawn |
NCT04863339 -
Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery
|
Phase 2 | |
| Terminated |
NCT00646308 -
Assessment of Cardiovascular Risk Markers in Growth Hormone Deficient Patients With Nonsecreting Pituitary Adenomas
|
N/A | |
| Recruiting |
NCT00852501 -
Characterization of Receptors in Non-functioning Pituitary Macroadenomas
|
Phase 4 | |
| Completed |
NCT03465423 -
Comparison of Propofol Requirement Between Patients With Pituitary Somatotroph Tumor and With Nonfunctioning Pituitary Tumor in Transsphenoidal Pituitary Surgery Under Total Intravenous Anesthesia
|
||
| Recruiting |
NCT03474601 -
Seoul National University Pituitary Disease Cohort Study
|
||
| Recruiting |
NCT05139277 -
Evaluation of the CONVIVO System
|
N/A | |
| Active, not recruiting |
NCT03636568 -
Hyponatremia Study (Delayed Hyponatremia After Pituitary Surgery)
|
N/A | |
| Completed |
NCT02813044 -
Effects of Total Intravenous Anesthesia With Propofol-remifentanil Versus Inhalational Anesthesia With Sevoflurane on Quality of Recovery in Patients Undergoing Transsphenoidal Surgery for Pituitary Tumor
|
N/A | |
| Recruiting |
NCT03973450 -
Epidemiology of Pituitary Tumours: Prevalence of Associated Neoplasia
|
||
| Active, not recruiting |
NCT04042753 -
Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors
|
Phase 2 | |
| Recruiting |
NCT04018963 -
The Impact of Endoscopic Pituitary Surgery on Nasal Function
|
||
| Not yet recruiting |
NCT04938401 -
Construction and Application of a Risk Prediction Model Forepistaxis After Pituitary Tumor Resection
|